Recruiting NA Familial Mediterranean Fever

New treatment option for Familial Mediterranean Fever

Official title Outcomes of Inspiratory Muscle Training in FMF Adolescents

ClinicalTrials.gov ID: NCT07129538

What this study is testing

What it's testing
Familial mediterranean fever (FMF) is common to be diagnosed before age of 18 . this disorder is connected with deterioration in exercise tolerance, pulmonary capacities, fatigue tolerance,

A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.

Who can take part

Ages 13 to 17

You may be able to join if

  • FMF adolecents
  • ages 13 -17 years
  • forty patients

You likely can't join if

  • cardiac problems
  • renal problems
  • liver problems
  • diabetes
  • brain problems

The study team makes the final eligibility decision.

Where it's taking place

  • Giza, Dokki, Egypt

Questions & answers

Do participants get paid in this trial?

This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.

Is it free to join, and do I need insurance?

Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.

How long does this study last?

The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.

Who can join this trial?

This study is enrolling all sexes, 13 years to 17 years. The study team makes the final eligibility decision.

Where is this trial taking place?

Study sites include Giza, Dokki, Egypt. Enter your location above to see the nearest site and check your eligibility.

Explore other conditions

BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.